Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.96 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 8/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicifadine SCHEMBL5443365 | 1.00 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL5436336 | 1.00 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL10235464 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520915 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520900 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL6003632 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL38793 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL1438038 | 0.95 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11075765 | 0.82 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL20995129 | 0.82 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165228-A1 | METHODS AND COMPOSITIONS EMPLOYING BICIFADINE FOR TREATING DISABILITY OR FUNCTIONAL IMPAIRMENT ASSOCIATED WITH ACUTE PAIN, CHRONIC PAIN, OR NEUROPATHIC DISORDERS | EBI LIFE SCIENCES INC (US) | 2017-06-15 | — | — | US | claimed |
| WO-2017066730-A1 | NOVEL METHODS | EBI LIFE SCIENCES, INC. (US) | 2017-04-20 | — | — | WO | claimed |
| WO-2017066729-A1 | NOVEL METHODS | EBI LIFE SCIENCES, INC. (US) | 2017-04-20 | — | — | WO | claimed |
| US-9393204-B2 | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders | EBI LIFE SCIENCES, INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| CN-101272684-A | Methods and compositions for the treatment of neuropathies and related disorders | DOV PHARMACEUTICAL INC (US) | 2008-09-24 | — | — | CN | claimed |
| EP-1915148-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| US-20080081834-A1 | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders | DOV PHARMACEUTICAL, INC. | 2008-04-03 | — | — | US | claimed |
| CN-1735594-A | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1562900-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV Pharmaceutical Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | claimed |
| WO-2004043920-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-6204284-B1 | ALCOHOL OR COCAINE ABUSE | AMERICAN CYANAMID COMPANY | 2001-03-20 | — | — | US | claimed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | claimed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165228-A1 | METHODS AND COMPOSITIONS EMPLOYING BICIFADINE FOR TREATING DISABILITY OR FUNCTIONAL IMPAIRMENT ASSOCIATED WITH ACUTE PAIN, CHRONIC PAIN, OR NEUROPATHIC DISORDERS | ACHE, NPFFR2, BDKRB2 | SLC6A2 1578/4885SLC6A4 2022/4885SLC6A3 2135/4885 |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | SLC6A2 1404/4885SLC6A4 783/4885SLC6A3 2236/4885 |
| US-20080081834-A1 | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders | ACHE, NPFFR2, BDKRB2 | SLC6A2 1578/4885SLC6A4 2022/4885SLC6A3 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.